CXCR2 and neoplasm: Importantly, the inhibition of CXCR2 with inhibitor navarixin was demonstrated to be effective in advanced mouse xenograft models in combination with enzalutamide, with the authors concluding that this combination may be effective in targeting both luminal and NE tumour cells, effectively addressing the heterogeneity seen in most cases of t-NEPC [141].